EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial

Wirksamkeit und Sicherheit von oralem Semaglutid vs. Sitagliptin in einer überwiegend chinesischen Population mit Typ-2-Diabetes, unter Metformin unzureichend kontrolliert: PIONEER 12, eine doppelblinde Phase-IIIa-randomisierte Studie

Linong Ji, Rikke M Agesen, Stephen C Bain, Fangming Fu, Sanaz Gabery, Jianlin Geng, Yiming Li, Yibing Lu, Bifen Luo, Wuyan Pang, Yi Tao, PIONEER 12 investigators

Diabetologia · 2024-09 · 67 (9) · 1800-1816

DOI: 10.1007/s00125-024-06133-4 ↗

Auf einen Blick

Orales Semaglutid senkte bei Typ-2-Diabetes unter Metformin HbA1c und Körpergewicht über 26 Wochen stärker als Sitagliptin. Die Verträglichkeit war insgesamt gut.

Fragestellung

Ist orales Semaglutid bei Typ-2-Diabetes unter Metformin wirksamer und sicherer als Sitagliptin?

Methode

Randomisierte, doppelblinde, doppel-dummy, aktiv kontrollierte Parallelgruppenstudie der Phase IIIa über 26 Wochen an 90 Zentren und 5 weiteren Ländern.

Ergebnisse

1441 randomisiert; 1438 in der Sicherheitsanalyse. HbA1c und Körpergewicht sanken mit oralem Semaglutid 3 mg, 7 mg und 14 mg stärker als mit Sitagliptin 100 mg; ETDs bei HbA1c –0,2, –0,7 und –1,0 Prozentpunkte.

Schlussfolgerung der Autor:innen

Orales Semaglutid führte über 26 Wochen zu signifikant stärkeren Reduktionen von HbA1c und Körpergewicht als Sitagliptin und war allgemein gut verträglich.

Kernaussagen

  • HbA1c-Reduktion unter oralem Semaglutid stärker als unter Sitagliptin
  • Auch das Körpergewicht sank mit allen Semaglutid-Dosen stärker
  • Unerwünschte Ereignisse waren vor allem gastrointestinal, meist mild/moderat

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Diabetologia, online erschienen am 10.07.2024. Verfasst von Linong Ji und 11 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Beijing, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Hypoglycemic Agents, Metformin. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk A/S.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims/hypothesis The aim of this study was to assess the efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes inadequately controlled with metformin treatment.

Methods

The Peptide Innovation for Early Diabetes Treatment (PIONEER) 12 trial was a randomised, double-dummy, active-controlled, parallel-group, Phase IIIa trial conducted over 26 weeks at 90 sites across the China region (including mainland China, Taiwan and Hong Kong) and five other countries. Adults aged ≥18 years (≥20 years in Taiwan) with a diagnosis of type 2 diabetes, HbA 1c between 53 and 91 mmol/mol (inclusive) and treated with a stable daily dose of metformin were eligible for inclusion. Participants were randomised (1:1:1:1) using a web-based randomisation system to either once-daily oral semaglutide (3 mg, 7 mg or 14 mg) or once-daily oral sitagliptin 100 mg. Treatment allocation was masked to both participants and investigators. Randomisation was stratified according to whether participants were from the China region or elsewhere. The primary endpoint was change in HbA 1c from baseline to week 26. The confirmatory secondary endpoint was change in body weight (kg) from baseline to week 26. All randomised participants were included in the full analysis set (FAS). All participants exposed to at least one dose of trial product were included in the safety analysis (SAS).

Results

Of 1839 participants screened, 1441 were randomly assigned to oral semaglutide 3 mg ( n =361), 7 mg ( n =360), 14 mg ( n =361) or sitagliptin 100 mg ( n =359) and included in the FAS. A total of 1438 participants were included in the SAS. In total, 75.2% of participants were from the China region. A total of 1372 (95.2%) participants completed the trial and 130 participants prematurely discontinued treatment (8.3%, 8.6% and 15.0% for oral semaglutide 3 mg, 7 mg and 14 mg, respectively; 4.2% for sitagliptin 100 mg). Significantly greater reductions in HbA 1c from baseline to week 26 were reported for all doses of oral semaglutide vs sitagliptin 100 mg. For oral semaglutide 3 mg, 7 mg and 14 mg vs sitagliptin 100 mg, the estimated treatment differences (ETDs [95% CI]) were –2 (–4, –1) mmol/mol, –8 (–9, –6) mmol/mol and –11 (–12, –9) mmol/mol, respectively. The corresponding ETDs (95% CI) in percentage points vs sitagliptin 100 mg were –0.2 (–0.3, –0.1), –0.7 (–0.8, –0.6) and –1.0 (–1.1, –0.8), respectively. Reductions in body weight were significantly greater for all doses of oral semaglutide vs sitagliptin 100 mg (ETD [95% CI] –0.9 [–1.4, –0.4] kg, –2.3 [–2.8, –1.8] kg and –3.3 [–3.8, –2.8] kg for 3 mg, 7 mg and 14 mg, respectively). In the subpopulation of participants from the China region (75.2% of trial participants), reductions in HbA 1c and body weight from baseline to week 26 were similar to those seen in the overall population. The most frequent adverse events in the semaglutide treatment arms were gastrointestinal, although these were mostly transient and mild/moderate in severity. Conclusions/interpretation Significantly greater reductions in both HbA 1c and body weight over 26 weeks were seen with oral semaglutide 3 mg, 7 mg and 14 mg than with sitagliptin 100 mg in a predominantly Chinese population with type 2 diabetes inadequately controlled with metformin treatment. Oral semaglutide was generally well tolerated, with a safety profile consistent with that seen in the global PIONEER trials.

Trial registration

ClinicalTrials.gov NCT04017832. Funding This trial was funded by Novo Nordisk A/S, Søborg, Denmark. Graphical Abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like PeptidesHypoglycemic AgentsMetforminSitagliptin PhosphateAdultAgedFemaleHumansMaleMiddle AgedAdministration, OralBlood GlucoseChinaDouble-Blind MethodEast Asian PeopleGlycated HemoglobinTreatment OutcomeTriazolesSemaglutide

Stichwörter der Autor:innen

GLP-1 analogueGlycaemic controlIncretin therapyPhase IIISemaglutideType 2 diabetes

Substanzen

Blood GlucoseGlucagon-Like PeptidesGlycated HemoglobinHypoglycemic AgentsMetforminSitagliptin PhosphateTriazolesSemaglutide

Autor:innen und Institutionen

  • Peking University People's Hospital, Beijing, China.
  • Novo Nordisk A/S, Søborg, Denmark.
  • Diabetes Research Unit, Swansea University, Swansea, UK. bainsc60@mail.com.
  • Jinan Central Hospital Affiliated to Shandong First Medical University, Jinan, China.
  • Harrison International Peace Hospital, Hengshui, China.
  • Huashan Hospital, Fudan University, Shanghai, China.

Förderung

  • Novo Nordisk A/S

Zitieren

APA

Ji, L., Agesen, R. M., Bain, S. C., Fu, F., Gabery, S., Geng, J., Li, Y., Lu, Y., Luo, B., Pang, W., Tao, Y., & PIONEER 12 investigators (2024). Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial. Diabetologia, 67(9), 1800-1816. https://doi.org/10.1007/s00125-024-06133-4

Vancouver

Ji L, Agesen RM, Bain SC, Fu F, Gabery S, Geng J, et al. Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial. Diabetologia. 2024;67(9):1800-1816. doi:10.1007/s00125-024-06133-4

BibTeX
@article{Ji2024,
  author = {Ji, Linong and Agesen, Rikke M and Bain, Stephen C and Fu, Fangming and Gabery, Sanaz and Geng, Jianlin and Li, Yiming and Lu, Yibing and Luo, Bifen and Pang, Wuyan and Tao, Yi and PIONEER 12 investigators, PIONEER 12 investigators},
  title = {Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial},
  journal = {Diabetologia},
  year = {2024},
  volume = {67},
  number = {9},
  pages = {1800--1816},
  doi = {10.1007/s00125-024-06133-4}
}
Kostenlos starten →